Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Ecnoglutide: First Approvals.

Drugs·2026
Same author

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026
Same author

Narsoplimab: First Approval.

Drugs·2026
Same author

Aficamten: First Approval.

Drugs·2026
Same author

Elamipretide: First Approval.

Drugs·2025

Related Experiment Video

Updated: Mar 7, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K

Daclizumab: A Review in Relapsing Multiple Sclerosis.

Matt Shirley1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Drugs
|February 18, 2017
PubMed
Summary

Daclizumab, a monoclonal antibody targeting CD25, effectively treats relapsing multiple sclerosis (MS) by reducing relapse rates and disease progression. It offers a new therapeutic option for MS patients, with maintained efficacy over time.

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic neurological disease.
  • Current disease-modifying therapies (DMTs) aim to reduce MS activity.
  • Daclizumab is a novel monoclonal antibody targeting the IL-2 receptor.

Purpose of the Study:

  • To evaluate the efficacy and safety of daclizumab in treating relapsing forms of MS.
  • To compare daclizumab's effectiveness against interferon beta-1a.
  • To assess long-term outcomes and quality of life improvements.

Main Methods:

  • Phase III DECIDE trial involving adult patients with relapsing-remitting MS.
  • Once-monthly subcutaneous administration of daclizumab.
  • Comparison with once-weekly intramuscular interferon beta-1a.

More Related Videos

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.9K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Related Experiment Videos

Last Updated: Mar 7, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.9K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Main Results:

  • Daclizumab demonstrated superiority over interferon beta-1a in reducing clinical relapse rates.
  • Significant reduction in radiological measures of MS disease activity was observed.
  • Daclizumab showed efficacy in reducing disability progression and improving quality of life.

Conclusions:

  • Daclizumab is an effective treatment for relapsing MS, offering a valuable alternative to existing DMTs.
  • Long-term efficacy is maintained over 3 years or more.
  • Adverse events are generally manageable with monitoring.